SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering ...

The financing round was jointly led by new investor Regeneron Ventures and current investor Deerfield Management.

NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc. (“ Exo-TOP ”), the Company’s ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...